News
Addex Awarded EuropaBio’s Most Innovative SME Award
Allosteric modulation company Addex Pharmaceuticals announced that the company has been awarded EuropaBio’s Most Innovative SME Award. This is the first time that the award has been presented and it attracted applications by 32 companies from 12 countries representing...
News
Fluxion Biosciences Announces Product Launch of BioFlux 1000Z
Fuxion Biosciences, Inc. announced that the new BioFlux 1000Z system for live cell imaging will be launched at the 50th American Society for Cell Biology Annual Meeting to be held December 11-15, 2010 in Philadelphia, PA. The BioFlux 1000Z...
News
GSK signs agreement to acquire Nanjing MeiRui Pharmaceuticals
GlaxoSmithKline plc announced that it has entered into an agreement to acquire Nanjing MeiRui Pharma Co., Ltd (MeiRui) for a cash consideration of approximately $70 million. Ninety per cent of the share capital of MeiRui is to be acquired...
News
Elan Drug Technologies Announces Completion of Enrolment in Phase 3
Elan Drug Technologies, a business unit of Elan Corporation, plc announced that Zogenix Inc, its licensee, has completed enrolment in its open-label Phase 3 study (Study 802) of ZX002, a novel, oral, single-entity, controlled-release formulation of hydrocodone. ZX002, which...
News
Aurobindo Pharma receives FDA tentative approval for Duloxetine Hydrochloride Delayed Release Capsules
Aurobindo Pharma Limited is pleased to announce that the company has received tentative approval from the US FDA to manufacture and market Duloxetine Hydrochloride Delayed-Release Capsules 20mg (base), 30mg (base) and 60mg (base). Duloxetine Hydrochloride Delayed-Release...
News
Amgen Highlights Data to Be Presented at American Society of Hematology Annual Meeting
Amgen announced that it will present data from several key Nplate(R) (romiplostim) studies at the 52nd Annual Meeting and Exposition of the ASH, Dec. 4-7, 2010, in Orlando, Fla. Results from six studies evaluating Nplate in adult patients with...
News
Merck to Acquire SmartCells, Inc
Merck & Co., Inc., and SmartCells, Inc., announced that they have entered into a definitive agreement under which Merck will acquire SmartCells, a private company developing a glucose responsive insulin formulation for the treatment of diabetes mellitus. ...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
